ahajournals.org1mon
Biochemical Effects of Losartan, a Nonpeptide Angiotensin II Receptor Antagonist, on the Renin-Angiotensin-Aldosterone System in Hypertensive Patients
Abstract We investigated the effects of angiotensin II (Ang II) type 1 receptor blockade with losartan on the renin-angiotensin-aldosterone system in hypertensive patients (supine diastolic blood ...
Medscape6d
Impact of Losartan on Stroke Risk in Hypertensive Patients in Primary Care
The angiotensin II type 1 receptor antagonist (angio-tensin receptor blocker [ARB]) losartan has been shown in the LIFE (Losartan Intervention for Endpoint Reduction in Hypertension) study to ...
Nature1mon
Blockade of the renin–angiotensin system in atrial fibrillation
Angiotensin II binding to AT1 receptors promotes synthesis of transforming growth factor β1 (TGF-β1), which leads to increased protein kinase activity and initiates a cascade of phosphorylation ...
Medscape18d
Angiotensin II-Receptor Antagonists: An Overview
Several clinical trials have demonstrated the relative tolerability of losartan. [8,14,18,19,20] The most frequent adverse reaction, as observed in a clinical trial of 2900 patients assessing the ...
BMJ6y
SAT0105 Losartan but not irbesartan reduces serum uric acid in hypertensive patients with gout
Background Losartan is the only angiotensin II receptor antagonist with uricosuric properties and has been shown to decrease serum uric acid (SUA) levels in normal subjects as well as in hypertensive ...